SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Metra, M.
Right arrow Articles by Dei Cas, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metra, M.
Right arrow Articles by Dei Cas, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Current guidelines in the pharmacological management of chronic heart failure

Marco Metra

Cardiologia, Dipartimento di Università di Brescia, Brescia, Italy, metramarco@ libero.it

Savina Nodari

Cardiologia, Dipartimento di Università di Brescia, Brescia, Italy

Livio Dei Cas

Cardiologia, Dipartimento di Università di Brescia, Brescia, Italy

Treatment of heart failure has undergone major changes in the last two decades. European and US guidelines have absorbed these major changes and set the new standards. It is therefore mandatory that treatment of heart failure is based on this knowledge. According to these guidelines, patients with chronic symptomatic heart failure should be treated with a diuretic and sometimes digoxin and vasodilators, to relieve symptoms, in addition to an angiotensin-converting enzyme inhibitor and/or an angiotensin receptor blocker (ARB) and a β-blocker to improve prognosis. An aldosterone antagonist should be added in patients with more advanced heart failure. Prevention of heart failure has also become a major goal.

We summarise here the major issues regarding the pharmacological treatment of chronic heart failure as indicated by the European and US guidelines.

Key Words: heart failure • guidelines • diuretics • β-blockers • angiotensin-converting enzyme inhibitors • cardiac glycosides • angiotensin receptor blockers • aldosterone antagonists

Journal of Renin-Angiotensin-Aldosterone System, Vol. 5, No. 1 suppl, S11-S16 (2004)
DOI: 10.3317/jraas.2004.018
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement